Biotech News
Related news
RVMDRevolution Medicines2026-09-02 21:50 EST
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
RVMDRevolution Medicines2026-10-05 12:00 EST
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
TEVATeva Pharmaceutical Industries2026-09-02 11:03 EST
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
REGNRegeneron Pharmaceuticals2026-10-01 15:30 EST
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
FATEFate Therapeutics2026-09-25 11:00 EST
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
GPCRStructure Therapeutics2026-09-08 12:00 EST
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
FATEFate Therapeutics2026-08-14 11:00 EST
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
CLDXCelldex Therapeutics2026-09-22 10:58 EST
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
LYELLyell Immunopharma2026-09-10 20:05 EST
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
Vaccinex
Vaccinex is a biotechnology company focused on antibody therapies and immunology, with a history of pursuing difficult oncology and neurodegenerative targets. Its story is tied to platform science and the challenge of turning it into durable value.
Recent company news
VCNXVaccinex2026-04-30 00:05 EST
Vaccinex Reports 2025 Annual Financial Results
VCNXVaccinex2025-12-23 13:01 EST
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
VCNXVaccinex2025-05-27 12:45 EST
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
VCNXVaccinex2025-04-21 12:45 EST
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
VCNXVaccinex2025-03-07 22:15 EST
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Stock data
- Close
- 1.03 USD
- Market cap
- —
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States